Sir,
Gastroesophageal reflux disease is the most common medical condition in Western countries (1) . A frequent complication of this condition is esophagitis, which is persistent in 50% of patients; up to 10% of such cases will progress to Barrett's esophagus (BE), which, in turn, predisposes the patient to the development of esophageal adenocarcinoma (2) . The concept of BE has changed significantly since its first description (3) . Based on the risk of malignancy, the heterogeneous spectrum of Barrett's metaplastic mucosa was recently reclassified into the following two distinct entities (4): (i) mucosa with specialized intestinal metaplasia (SIM) identified by the presence of goblet and columnar non-goblet cells in a villous or flat configuration; and (ii) mucosa without SIM recognized by a gastric (atrophic fundic or junctional) architectural organization containing mucous columnar non-goblet cells but no goblet cells. It has been shown that in Barrett's esophagus premalignant lesions arise in metaplastic tissue containing goblet cells (5) . This feature has recently been recognized as the histological hallmark for the diagnosis of Barrett's metaplasia, allowing the selection of high-risk patients for endoscopic surveillance. By contrast, columnar non-goblet cells have been a neglected element in the understanding of the mechanism of Barrett's metaplasia despite their much higher prevalence than that of goblet cells (6) . Such non-goblet cells are rather heterogeneous and their role in the progression towards malignancy has not yet been clarified. The expression of small intestine enzymes by both columnar non-goblet metaplastic cells and Barrett's-associated adenocarcinoma cells has recently been reported, which suggests that cells with a non-terminally differentiated enterocytic phenotype might also constitute a marker for cancer risk (7) . Consequently, the investigation of Barrett's epithelium only on the basis of hematoxylineosin histological features may underestimate the cancer risk. Therefore, biological markers of an enterocytic or gastric phenotype are still necessary for a more precise functional differentiation of Barrett's epithelium.
The human pepsinogens PGA and PGC are aspartic proteases produced in the gastric mucosa and secreted into the lumen; they play a major role in the digestion of proteins after activation at acid pH (8) . PGA is only ex-pressed in the mucosa of the gastric fundus, whereas PGC is expressed by all regions of the gastric mucosa (9) . Thus, PGC may be considered as a biological marker of the complete functional differentiation of all gastric epithelium. The aim of this preliminary study was to evaluate the expression of PGC in Barrett's epithelium and its possible relationship with the morphological features of this condition.
Tissue specimens were retrieved by endoscopy from 21 patients with BE whose characteristics are shown in Table I . A diagnosis of BE was suggested when endoscopy revealed the distal esophagus to be covered with columnar epithelium; histological confirmation was obtained in all cases of metaplastic columnar epithelium. Such epithelium was classified into two types as described above (4) .
PGC purification and antiserum production were performed as described elsewhere (10) . Immunohistochemical assays were performed on 5-mm formalinfixed, paraffin-embedded tissue sections using the streptavidin-biotin supersensitive method (Biogenex, San Ramon, CA). Incubation with antiserum against PGC (diluted 1:500 in 20 mM phosphate buffer, pH 7.2, and 1% bovine serum albumin) was performed at room temperature for 30 min. The slides were then incubated for 20 min with the second biotinylated antibody obtained from Biogenex and for another 20 min with the streptavidinalkaline phosphatase complex reagent (Biogenex) at room temperature; the reaction was developed with Fast Red in tris buffer (pH 7.2) containing naphtol-phosphate. Lastly, the slides were counterstained with Mayer's hematoxylin and mounted in Aquatex (Merck, Darmstadt, Germany). The staining specificity was determined using controls that involved incubation of tissue sections with buffer alone or with an equal amount of IgG from non-immunized rabbits. There was no significant staining in either case. Furthermore, immunostaining was completely abolished by antiserum preincubation with PGC purified from gastric mucosa. A case was considered positive if there was unequivocal cytoplasmic expression of the antigen in the cells of metaplastic glands. The relationship between PGC staining and clinicopathological factors was examined by the chi-square test with Yates' correction.
With regard to the two major cell types of the meta-plastic mucosa, only the columnar non-goblet cells expressed PGC. Table I shows the expression of PGC in all cases of Barrett's mucosa with and without SIM. PGC was expressed by columnar non-goblet cells in 13.3% (2/15 cases) of areas with SIM, and in 73.7% (14/19 cases) of areas without SIM (p=0.002).
The results show a significant, positive association between Barrett's epithelium without SIM and PGC expression. Nevertheless, a substantial percentage of cases of this type of epithelium, with a gastric-like histological appearance, did not show PGC expression, suggesting that they may correspond to an incomplete form of gas-tric metaplasia. In the present study we also found that certain cases of columnar epithelium with SIM present areas showing PGC immunostaining, which suggests their functional gastric differentiation or a non-terminally differentiated enterocytic phenotype.
In conclusion, although the diagnosis of Barrett's epithelium is routinely made on the basis of hematoxylineosin histological features, this method may underestimate intermediate stages of differentiation towards a fully gastric or enterocytic phenotype. Accordingly, our results lead us to suggest that PGC expression may represent a useful biological marker to solve inconclusive cases, which is a problem in daily practice, and this may have clinical implications for the diagnosis and management of patients with BE. In addition, further studies on PGC expression in BE may contribute to elucidating the biopathogenesis of BE, as well as the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. 
